Nav: Home

Treatment rapidly reverses the effect of blood thinner dabigatran

July 11, 2017

PHILADELPHIA -- At least 28 million prescriptions for blood thinners are filled by pharmacists yearly for the irregular heartbeat of atrial fibrillation, deep vein thrombosis, and other indications, according to the Department of Health and Human Services. However, on rare occasions, anticoagulants can present risks of accidental bleeding and hemorrhage or can delay emergency surgery. A newly completed phase III clinical study demonstrates the safety and efficacy of idarucizumab, a novel therapy that acts as an antidote to the blood thinner dabigatran.

"Prior to idarucizumab, there was no rapid, reliable, and effective method for reversing dabigatran and other orally administered blood thinners, which otherwise may take at least 12 to 24 hours to clear from the body," says first and corresponding author Charles Pollack, M.D., Professor of Emergency Medicine at Sidney Kimmel Medical College of Thomas Jefferson University. Dr. Pollack also serves as Associate Provost of Thomas Jefferson University. "Physicians will now have a potentially life-saving option for treating patients at risk of uncontrolled bleeding or in need of emergency surgery."

The results of the RE-VERSE AD clinical trial were published in The New England Journal of Medicine on July 11.

The study enrolled 503 patients taking dabigatran in 39 countries between 2014 and 2016, who had an urgent medical need to reverse the blood thinner. Patients were grouped by those who had uncontrolled bleeding or hemorrhage and those who required emergency surgery that could not be safely performed under anticoagulation. All patients received one dose of five grams of idarucizumab; only nine received a second dose. The researchers checked the blood for various measures of clotting ability before the reversal agent was administered and then at six time points afterwards to assess the therapy's speed and efficacy.

Idarucizumab was able to return patients to normal clotting function within minutes of administration (the first tested time point was between 10-30 minutes after therapy was given). The researchers saw that in patients with uncontrolled bleeding, idarucizumab was able to stop the bleeding within a median of 2.5 hours. Those requiring surgery were able to begin the procedure at a median of 1.6 hours.

The therapy, idarucizumab, from Boehringer Ingelheim Pharmaceuticals, is made from an antibody segment that functions by binding tightly and specifically to dabigatran and preventing the anticoagulant from working. As such, the therapy is only an effective antidote to dabigatran and not other anticoagulants.

Interim results of this study were published in 2015 and included the analysis of results from 90 patients. Based on those results and consistent findings from pre-clinical studies, the US Food and Drug Administration and the European Medicines Agency both granted approval for use of the drug in emergency settings. The current study confirms and strengthens the interim findings.

"For the first time we have the ability to turn off oral anticoagulation like a light switch," says Dr. Pollack. "In the past, we haven't had the ability to do that."
The study was funded by Boehringer Ingelheim Pharmaceuticals. The authors report no additional conflicts of interest.

Article reference: C.V. Pollack et al., "Dabigatran Reversal with Idarucizumab," NEJM, DOI: 10.1056/NEJMoa1707278, 2017.

About Jefferson

Jefferson, through its academic and clinical entities of Thomas Jefferson University and Jefferson Health, including Abington Health and Aria Health, is reimagining health care for the greater Philadelphia region and southern New Jersey. Jefferson has 23,000 people dedicated to providing the highest-quality, compassionate clinical care for patients, educating the health professionals of tomorrow, and discovering new treatments and therapies to define the future of care. With a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 35 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.

Thomas Jefferson University

Related Blood Thinner Articles:

Treatment rapidly reverses the effect of blood thinner dabigatran
A new treatment rapidly removes the oral blood thinner dabigatran (PRADAXA®) from circulation within minutes, allowing life-saving clots to form normally.
Want to feel stronger and thinner? Get some exercise
Just one 30-minute bout of exercise makes women feel stronger and thinner, according to a new UBC study.
New sound diffuser is 10 times thinner than existing designs
The new, 'ultra-thin' sound diffuser is 10 times thinner than the widely used diffusers found in recording studios, concert venues and movie theaters to reduce echoes and improve the quality of sound.
Researchers use modified insulin and red blood cells to regulate blood sugar
Researchers have developed a new technique that uses modified insulin and red blood cells to create a glucose-responsive 'smart' insulin delivery system.
New blood thinner better at preventing recurrent blood clots than aspirin
An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs, according to a study being published in the New England Journal of Medicine and presented at the American College of Cardiology's 66th Annual Scientific Session.
Blood test for prion disease could make blood supply safer
A blood test accurately diagnosed a total of 32 patients with a rare form of prion disease, two new analyses report, offering a potentially valuable tool for preventing prion contamination of the blood supply.
'Reversible' blood thinner may cut bleeding risk
In an academic-industrial collaboration, researchers have developed an antibody that blocks the formation of blood clots without triggering bleeding, a serious risk associated with current blood thinners.
'Fixing' blood vessel cells to diagnose blood clotting disorders
A new device developed at the Wyss Institute for Biologically Inspired Engineering could monitor blood clot formation and diagnose effectiveness of anti-platelet therapy by microengineering tiny hollow channels lined by chemically 'fixed' human endothelial cells that more closely mimic cellular and vascular flow conditions inside a patient's body than a bare surface.
New technique uses electrical conductivity to measure blood in dry blood spot analysis
Researchers from The University of Texas at Arlington have demonstrated that electrical conductivity can be an effective means to precisely measure the amount of blood present in dry blood spot analysis, providing a new alternative to the current preferred approach of measuring sodium levels.
Blood management guidelines can reduce blood wastage and save millions of dollars
Improving the processes of ordering, transporting, and storing blood can save millions of dollars and drastically reduce blood wastage, reported a research team from one academic medical center after implementing institutional initiatives to address blood management.

Related Blood Thinner Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...